单位：[1]Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH[2]Cardiff Institute of Infection & Immunity, Heath Park, Cardiff, UK[3]University of Michigan, Ann Arbor, MI[4]Tufts University School of Medicine, Boston, MA[5]Federal University of Sao Paulo, Sa˜o Paulo, Brazil[6]Danish Pain Research Center, Aarhus University, Aarhus, Denmark[7]Hyogo College of Medicine, Hyogo[8]Multidisciplinary Pain Center, Aichi Medical University, Nagakute, Aichi, Japan[9]Cedars-Sinai Medical Center, Los Angeles, CA[10]China-Japan Friendship Hospital, Beijing, China.
This manuscript, developed by a group of chronic pain researchers and clinicians from around the world, aims to address the state of knowledge about fibromyalgia (FM) and identify ongoing challenges in the field of FM and other chronic pain syndromes that may be characterized by pain centralization/amplification/hypersensitivity. There have been many exciting developments in research studies of the pathophysiology and treatment of FM and related syndromes that have the potential to improve the recognition and management of patients with FM and other conditions with FM-like pain. However, much of the new information has not reached all clinicians, especially primary care clinicians, who have the greatest potential to use this new knowledge to positively impact their patients' lives. Furthermore, there are persistent misconceptions about FM and a lack of consensus regarding the diagnosis and treatment of FM. This paper presents a framework for future global efforts to improve the understanding and treatment of FM and other associated chronic pain syndromes, disseminate research findings, identify ways to enhance advocacy for these patients, and improve global efforts to collaborate and reach consensus about key issues related to FM and chronic pain in general.
基金：
Pfizer Inc., New York, NYPfizer; Dainippon Sumitomo Pharma, Tokyo, Japan; Innovative Med Concepts LLC (IMC), Tuscaloosa, AL; Ironwood Pharmaceuticals, Cambridge, MA; Purdue Pharma, Stamford, CT; Shire, Lexington, MA; Theravance Biopharma, South San Francisco, CA; Toray, Tokyo, Japan; Eli Lilly and Company, Indianapolis, INEli Lilly; Forest Laboratories, New York, NY; Tonix Pharmaceuticals, New York, NY; Cerephex Corporation, Los Altos, CA; National Institutes of Health, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Grunenthal, Aachen Germany; Orion Pharma, Espoo, Finland
第一作者单位：[1]Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH[*1]University of Cincinnati College of Medicine, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219
通讯作者：
通讯机构：[1]Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH[*1]University of Cincinnati College of Medicine, 260 Stetson Street, Suite 3200, Cincinnati, OH 45219
推荐引用方式(GB/T 7714)：
Arnold Lesley M.,Choy Ernest,Clauw Daniel J.,et al.Fibromyalgia and Chronic Pain Syndromes A White Paper Detailing Current Challenges in the Field[J].CLINICAL JOURNAL of PAIN.2016,32(9):737-746.doi:10.1097/AJP.0000000000000354.
APA：
Arnold, Lesley M.,Choy, Ernest,Clauw, Daniel J.,Goldenberg, Don L.,Harris, Richard E....&Wang, Guochun.(2016).Fibromyalgia and Chronic Pain Syndromes A White Paper Detailing Current Challenges in the Field.CLINICAL JOURNAL of PAIN,32,(9)
MLA：
Arnold, Lesley M.,et al."Fibromyalgia and Chronic Pain Syndromes A White Paper Detailing Current Challenges in the Field".CLINICAL JOURNAL of PAIN 32..9(2016):737-746
